In the serotonin pathway, TPH1 mRNAs was significantly upregulated in MCAO brains, with increased thrombosis and thromboembolism risk [198], and TPH1 variants were found to be more frequent in heterozygous form in the control group compared to the group of ischemic stroke patients [199], implicating a preventive and therapeutic strategy at the RNA and gene levels. This evidence concerns the gene TPH1 and Thromboembolism.